Does minocycline have antidepressant effect?

Biomedicine and Pharmacotherapy

Volumn 62, Issue 5, 2008, Pages 308-311

  Pae, Chi Un ^a,b   Marks, David M ^b   Han, Changsu ^b,c   Patkar, Ashwin A ^b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Korea University College of Medicine   (South Korea)

Author keywords

Anti inflammatory effect; Depression; Minocycline; Neuroprotection

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LITHIUM; MALONALDEHYDE; MINOCYCLINE; SUPEROXIDE DISMUTASE; TIANEPTINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DRUG EFFICACY; DRUG POTENTIATION; EXCITOTOXICITY; FORCED SWIMMING TEST; HAMILTON SCALE; HUMAN; LIPID PEROXIDATION; MAJOR DEPRESSION; MONOTHERAPY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; ORGANIC BRAIN SYNDROME; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SOMATOFORM DISORDER; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; HUMANS; MINOCYCLINE; MODELS, ANIMAL; NEUROPROTECTIVE AGENTS;

EID: 44349129208     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.12.005     Document Type: Article

References (32)

1. Skolnick P. Beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry 63 Suppl. 2 (2002) 19-23
2. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry 19 1 (1995) 11-38
3. Owen B.M., Eccleston D., Ferrier I.N., and Young A.H. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 103 3 (2001) 226-228
4. Tuglu C., Kara S.H., Caliyurt O., Vardar E., and Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 170 4 (2003) 429-433
5. Perera T.D., Coplan J.D., Lisanby S.H., Lipira C.M., Arif M., Carpio C., et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 27 18 (2007) 4894-4901
6. Czeh B., and Lucassen P.J. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?. Eur Arch Psychiatry Clin Neurosci 257 5 (2007) 250-260
7. Traynor B.J., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S.C., et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67 1 (2006) 20-27
8. Investigators NN-P. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 5 (2006) 664-671
9. Zhang L., Shirayama Y., Shimizu E., Iyo M., and Hashimoto K. Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 544 1-3 (2006) 1-9
10. Lai A.Y., and Todd K.G. Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. Glia 53 8 (2006) 809-816
11. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 38 2 (2007) 247-252
12. Fumagalli F., Molteni R., Calabrese F., Frasca A., Racagni G., and Riva M.A. Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem 93 6 (2005) 1551-1560
13. Warner-Schmidt J.L., and Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16 3 (2006) 239-249
14. Chiou S.H., Chen S.J., Peng C.H., Chang Y.L., Ku H.H., Hsu W.M., et al. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 343 2 (2006) 391-400
15. Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrun G., van Kampen M., et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 98 22 (2001) 12796-12801
16. Manji H.K., Moore G.J., and Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 48 8 (2000) 740-754
17. Ekdahl C.T., Claasen J.H., Bonde S., Kokaia Z., and Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 100 23 (2003) 13632-13637
18. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., and Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64 1 (2001) 43-51
19. Maes M., De Vos N., Pioli R., Demedts P., Wauters A., Neels H., et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 58 3 (2000) 241-246
20. Kraus R.L., Pasieczny R., Lariosa-Willingham K., Turner M.S., Jiang A., and Trauger J.W. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 94 3 (2005) 819-827
21. Hashimoto K., Sawa A., and Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62 11 (2007) 1310-1316
22. Mauri M.C., Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37 3 (1998) 124-129
23. Maes M., Verkerk R., Vandoolaeghe E., Lin A., and Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 97 4 (1998) 302-308
24. Coric V., Milanovic S., Wasylink S., Patel P., Malison R., and Krystal J.H. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 167 2 (2003) 219-220
25. Pi R., Li W., Lee N.T., Chan H.H., Pu Y., Chan L.N., et al. Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem 91 5 (2004) 1219-1230
26. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry, in press.
27. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuro-Psychopharmacol Biol Psychiatry, in press.
28. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 5604 (1977) 730-732
29. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121 1 (1995) 66-72
30. Hunter C.L., Quintero E.M., Gilstrap L., Bhat N.R., and Granholm A.C. Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. Eur J Neurosci 19 12 (2004) 3305-3316
31. Hua X.Y., Svensson C.I., Matsui T., Fitzsimmons B., Yaksh T.L., and Webb M. Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur J Neurosci 22 10 (2005) 2431-2440
32. Levine J., Cholestoy A., and Zimmerman J. Possible antidepressant effect of minocycline. Am J Psychiatry 153 4 (1996) 582